DIFFUSION TENSOR IMAGING IN FIRST EPISODE SCHIZOPHRENIA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 很少有描述是针对理解精神分裂症患者在抗精神病药物治疗前白色物质微结构异常的作用，以及这些药物对白色物质完整性测量的潜在影响。在这项初步研究中，我们计划调查白色物质异常，使用扩散张量成像（DTI），在首次发作的精神分裂症患者在治疗开始，然后经过12周的标准化治疗。假设患者将在基线时表现出额叶和颞叶的白色物质异常，并且抗精神病药物治疗后这些区域的白色物质完整性将增加。这些数据将用于证明收集纵向DTI数据的可行性，以便将来向NIMH提交拨款。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Little description has been directed at understanding the role of white matter microstructural abnormalities in schizophrenia prior to treatment with antipsychotic agents and the potential effects of these medications on measures of white matter integrity. In this pilot study, we plan to investigate white matter abnormalities, using diffusion tensor imaging (DTI), in patients experiencing a first-episode of schizophrenia at the onset of treatment and then following 12 weeks of standarized treatment. It is hypothesized that patients will demonstrate white matter abnormalities in the frontal and temporal lobes at the baseline and that increases in white matter integrity will occur in these regions following antipsychotic treatment. This data will be used to demonstrate feasibility of collection of longitudinal DTI data for a future grant submission to the NIMH.